-
Pembrolizumab, sold
under the
brand name Keytruda, is a
humanized antibody, more
specifically a PD-1 inhibitor, used in
cancer immunotherapy that treats...
- Favezelimab/
pembrolizumab is a fixed-dose
combination of two
monoclonal antibodies developed by
Merck to
treat various cancers. Timmerman, John; Lavie...
-
drugs or products, each with over $1
billion in revenue:
Keytruda (
pembrolizumab), a
humanized antibody used in
cancer immunotherapy that had $14.3 billion...
-
checkpoint inhibitors include antibodies such as ipilimumab, nivolumab, and
pembrolizumab.
Dendritic cell
therapy provokes anti-tumor
responses by
causing dendritic...
- As
adjuvant therapy, mRNA-4157
monotherapy and in
combination with
pembrolizumab have been
investigated in
patients with
resected solid tumors (melanoma...
- system.
Atezolizumab is an anti-PD-L1
monoclonal antibody.
Nivolumab and
Pembrolizumab are anti-PD-1
monoclonal antibodies.
Ipilimumab is a
monoclonal antibody...
- 's
Keytruda (
pembrolizumab); its
success has been
described as
important for the
pharmaceutical industry in China.
Nivolumab Pembrolizumab "国家药监局批准依沃西单抗注射液上市"...
-
treatment options.
Pembrolizumab monotherapy is an
appealing approach for
these patients, with
median OS of 30
months with
pembrolizumab single agent compared...
-
clinical and
observational studies,
immune checkpoint inhibitors (e.g.,
pembrolizumab) have been
tested in
mucosal melanomas and have
shown promising response...
-
response rate with
median progression free
survival of 10.5
months Pembrolizumab: 12%
objective response rate with
median progression free
survival of...
